Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tesofensine - Saniona

Drug Profile

Tesofensine - Saniona

Alternative Names: NS-2330; Tesofensine

Latest Information Update: 22 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NeuroSearch
  • Developer Medix; Saniona
  • Class Antidementias; Antiparkinsonians; Chlorobenzenes; Heterocyclic bicyclo compounds; Neuroprotectants; Nootropics; Obesity therapies; Small molecules
  • Mechanism of Action Biogenic monoamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Obesity
  • Discontinued Alzheimer's disease; Parkinson's disease

Most Recent Events

  • 29 Jan 2019 Phase-II clinical trials in Obesity (Combination therapy) in Denmark (PO) (EudraCT2018-003672-12) (NCT03845075)
  • 01 Jan 2019 Medix completes a phase III trial in Obesity in Mexico before January 2019
  • 17 Dec 2018 Efficacy and adverse events data from the phase III Viking trial in Obesity released by Saniona
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top